AU2022269602A1 - Fusion polypeptides - Google Patents

Fusion polypeptides Download PDF

Info

Publication number
AU2022269602A1
AU2022269602A1 AU2022269602A AU2022269602A AU2022269602A1 AU 2022269602 A1 AU2022269602 A1 AU 2022269602A1 AU 2022269602 A AU2022269602 A AU 2022269602A AU 2022269602 A AU2022269602 A AU 2022269602A AU 2022269602 A1 AU2022269602 A1 AU 2022269602A1
Authority
AU
Australia
Prior art keywords
fusion polypeptide
polypeptide
metal
hydroxide
complex
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2022269602A
Other languages
English (en)
Inventor
Darrell Irvine
Michael Schmidt
Karl Dane Wittrup
Grigorios Zarbis-Papastoitsis
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ankyra Therapeutics Inc
Original Assignee
Ankyra Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ankyra Therapeutics Inc filed Critical Ankyra Therapeutics Inc
Publication of AU2022269602A1 publication Critical patent/AU2022269602A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5434—IL-12
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/11—Protein-serine/threonine kinases (2.7.11)
    • C12Y207/11001—Non-specific serine/threonine protein kinase (2.7.11.1), i.e. casein kinase or checkpoint kinase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU2022269602A 2021-05-05 2022-05-04 Fusion polypeptides Pending AU2022269602A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163184620P 2021-05-05 2021-05-05
US63/184,620 2021-05-05
PCT/US2022/027617 WO2022235755A2 (en) 2021-05-05 2022-05-04 Fusion polypeptides

Publications (1)

Publication Number Publication Date
AU2022269602A1 true AU2022269602A1 (en) 2023-11-09

Family

ID=82020825

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2022269602A Pending AU2022269602A1 (en) 2021-05-05 2022-05-04 Fusion polypeptides

Country Status (8)

Country Link
US (3) US12454695B2 (https=)
EP (1) EP4334337A2 (https=)
JP (1) JP2024517855A (https=)
KR (1) KR20240028341A (https=)
AU (1) AU2022269602A1 (https=)
CA (1) CA3217079A1 (https=)
IL (1) IL308240A (https=)
WO (1) WO2022235755A2 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4334337A2 (en) 2021-05-05 2024-03-13 Ankyra Therapeutics, Inc. Fusion polypeptides
CA3234552A1 (en) 2021-10-20 2023-04-27 Synthekine, Inc. Heterodimeric fc cytokines and uses thereof
JP2025540624A (ja) * 2022-11-09 2025-12-16 アンキラ セラピューティクス，インコーポレイテッド 融合ポリペプチドを作製する方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2019346335B2 (en) * 2018-09-28 2024-07-25 Massachusetts Institute Of Technology Collagen-localized immunomodulatory molecules and methods thereof
WO2020263399A1 (en) 2019-06-26 2020-12-30 Massachusetts Institute Of Technology Immunomodulatory fusion protein-metal hydroxide complexes and methods thereof
EP4334337A2 (en) 2021-05-05 2024-03-13 Ankyra Therapeutics, Inc. Fusion polypeptides

Also Published As

Publication number Publication date
US20260035706A1 (en) 2026-02-05
WO2022235755A3 (en) 2022-12-29
EP4334337A2 (en) 2024-03-13
CA3217079A1 (en) 2022-11-10
KR20240028341A (ko) 2024-03-05
US20220372495A1 (en) 2022-11-24
US20250327085A1 (en) 2025-10-23
JP2024517855A (ja) 2024-04-23
IL308240A (en) 2024-01-01
WO2022235755A2 (en) 2022-11-10
US12454695B2 (en) 2025-10-28

Similar Documents

Publication Publication Date Title
US20250327085A1 (en) Fusion polypeptides
KR102355950B1 (ko) Tigit에 대한 항체
CN107922477B (zh) 用于选择性制造抗体-药物缀合物的方法
JP7611173B2 (ja) 組換えｆａｐ結合タンパク質及びそれらの使用
CN107683289B (zh) IL13Rα2结合剂和其在癌症治疗中的用途
WO2021213478A1 (zh) 抗人b7-h3的单克隆抗体及其应用
CN111032688A (zh) 用于延长的血清半衰期的工程化抗体fc变体
JP6574257B2 (ja) 新規の抗Ｎｏｄａｌ抗体及びその使用方法
KR20170138494A (ko) 항-ｔｙｒ０３ 항체 및 이의 용도
US12552867B2 (en) Single chain fusionconstructs comprising multimeric antibody fragments fused to collagen trimerization domains
US20220281939A1 (en) Modified tff2 polypeptides
WO2021102624A1 (en) Covalent protein drugs developed via proximity-enabled reactive therapeutics (perx)
WO2022089644A1 (zh) 靶向cd5的全人源抗体、全人源嵌合抗原受体(car)及其应用
KR102231685B1 (ko) 인간 항-il-32 항체
JP2026063000A (ja) Ｇｐ１３０結合分子および使用方法
US20230279126A1 (en) Il23 receptor synthetic cytokines and methods of use
KR20230060527A (ko) Pd-1 폴리펩티드 변이체
CN113366020A (zh) 抗pd-l1的新型抗体及其用途
CA3170750A1 (en) Serum albumin binding nanobody compositions and methods for using the same
US20250339495A1 (en) Fusion polypeptides and formulations thereof
WO2025179282A1 (en) Antibodies targeting epstein-barr virus proteins and methods of use
CN121773135A (zh) 白细胞介素-13受体亚基α-2结合剂和其用途
PL244962B1 (pl) Przeciwciało anty-FOLR1 i jego zastosowanie w medycynie
TW202600601A (zh) Ｔｒｏｐ２特異性抗原結合蛋白與細胞激素之共軛物
HK40103919A (zh) 蛋白酶活化的多肽